The Advanced Practitioner's Guide to Multiple Myeloma
A continuing education activity for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Click here for continuing education information.
After reviewing the articles in this supplement, click on the "How to Earn Credit" page for instructions on how to take the learning assessment, complete the evaluation form, and earn credit.
This CME/CE/CEU accredited supplement is jointly provided by
This supplement has been developed by members of the International Myeloma Foundation Nurse Leadership Board
Page Bertolotti, RN, BSN, OCN, Samuel Oschin Cancer Center at Cedars-Sinai Medical Center
Kevin Brigle, PhD, NP, VCUHS Massey Cancer Center
Donna D. Catamero, ANP-BC, OCN, CCRC, Mount Sinai Medical Center
Kathleen Colson, RN, BSN, BS, Dana-Farber Cancer Center
Hollie Devine, MSN, ANP-BC, The Ohio State University Medical Center James Cancer Hospital
Deborah Doss, RN, OCN, Dana-Farber Cancer Center
Beth Faiman, PhD, MSN, APRN-BC, AOCN, Cleveland Clinic Taussig Cancer Institute
Elizabeth Finley-Oliver, RN, BSN, OCN, H. Lee Moffitt Cancer Center and Research Institute
Charise Gleason, MSN, NP-BC, AOCNP, Winship Cancer Institute of Emory University
Sandra Kurtin, RN, MSN, AOCN, ANP-C, The University of Arizona Cancer Center
Patricia A. Mangan, RN, MSN, APRN-BC, Abramson Cancer Center at the University of Pennsylvania
Ali McBride, PharmD, MS, BCPS, BCOP, The University of Arizona Cancer Center
Ann McNeill, RN, MSN, APN, John Theurer Cancer Center at HUMC
Teresa Miceli, RN, BSN, OCN, Mayo Clinic-Rochester
Kimberly Noonan, RN, ANP, AOCN, Dana-Farber Cancer Center
Tiffany Richards, MS, ANP, AOCNP, MD Anderson Cancer Center
Sandra Rome, RN, MN, AOCN, CNS, Cedars-Sinai Medical Center
Joseph Tariman, PhD, ANP-BC, DePaul University
Daniel Verina, BS, BSN, MSN, ACNP-BC, Mount Sinai Medical Center
This supplement is provided by independent educational grants from the following companies: Takeda Oncology, Celgene Corporation, Binding Site, and Adaptive Biotechnologies.